Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbations of chronic bronchitis

Journal of Chemotherapy

Volumn 12, Issue 3, 2000, Pages 216-222

  Cazzola, Mario ^c   Di Perna, F ^c   Boveri, B ^a   Di Marco, F ^a   Diamare, F ^b   Centanni, S ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Ospedale G da Procida   (Italy)

^c NONE

Author keywords

Acute exacerbations of chronic bronchitis; Bronchitis; Cefaclor; Cephalosporins; Pharmacodynamic breakpoint; Pharmacodynamics; Pharmacokinetics; Time above MIC

Indexed keywords

CEFACLOR;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC BRONCHITIS; CLINICAL ARTICLE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; SUSTAINED RELEASE FORMULATION;

EID: 0034049725     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2000.12.3.216     Document Type: Article

References (21)

1. 1 Cazzola M, Matera MG, Donner CF. Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implication for treatment of community-acquired lower respiratory tract infections. Clin Drug Invest 1998; 16: 335-346.
2. 2 Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in acute otitis media. Pediatr Infect Dis J 1996; 15 (Suppl 3): 255-259.
3. 3 Preston DA. Global surveillance of bacterial susceptibility to cefaclor: 1988-1990. Clin Ther 1993; 15: 88-96.
4. 4 Cazzola M. Problems and perspectives in the antibiotic treatment of lower respiratory tract infections. Pulm Pharmacol 1994; 7: 139-152.
5. 5 Brumfitt W, Hamilton-Miller JMT. Cefaclor into the millennium. J Chemother 1999; 11: 163-178.
6. 6 Brumfitt W. Introductory remarks. Postgrad Med J 1992; 68 (Suppl 3): S1-S2.
7. 7 Cazzola M, Matera MG, Cirella M, et al. Penetrazione del cefaclor nell'espettorato dopo somministrazione singola e multipla: confronto fra la preparazione a rilascio classico e una formulazione a rilascio modificato. Giorn It Ric Clin Ter 1995; 16: 37-41.
8. 8 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152: S72-S120.
9. rd ed. Baltimore: The Williams & Wilkins Co, 1991: 313.
10. 10 Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 (Suppl A): 45-57.
11. 11 Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143-160.
12. 12 Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998; 77 (6 Suppl): 7-11.
13. 13 Highet VS, Forrest A, Ballow CH, Schentag JJ. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 1999; 43 (Suppl A): 55-63.
14. 14 Cazzola M, Diamare F, Vinciguerra A, Salzillo A, Calderaro F. La penetrazione polmonare degli antibiotici e il suo impatto clinico. Rass Pat App Respir 1996; 11: 134-147.
15. 15 Cars O. Efficacy of b-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis 1997; 27: 29-33.
16. 16 Peterson LR, Hall WH, Zinneman HH, Gerding DN. Standardization of a preparative ultracentrifuge method for quantitative determination or protein binding of seven antibiotics. J Infect Dis 1977; 136: 778-783.
17. 17 Cappelletty DM, Rybak MJ. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 1996; 40: 1148-1152.
18. 18 Verhaegen J, Verbist L. In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 1998; 41: 381-385.
19. 19 Acar JF. Resistance patterns of Haemophilus influenzae. J Chemother 1999; 11 (Suppl 1): 44-50.
20. 20 Garau J. Basing empiric treatment choices for respiratory tract infection on the results of the Alexander Project. J Chemother 1999; 11 (Suppl 1): 51-55.
21. 21 Cazzola M, Matera MG. Interrelationship between pharmacokinetics and pharmacodynamics in the design of dosage regimens for treating acute exacerbations of chronic bronchitis, Respir Med 1998; 92: 895-901.